Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Inclusion Criteria: * Confirmed diagnosis of a hematologic malignancy (e.g., leukemia, lymphoma, myelodysplastic syndrome). * Proven, probable, or possible invasive mucormycosis according to the 2019 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria. * Age ≥18 years and ≤65 years at enrollment. * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2. * No clinically significant organ dysfunction (e.g., renal, hepatic, cardiac) at screening that would preclude protocol-defined therapies. * Ability to understand the study procedures and provide voluntary written informed consent. Exclusion Criteria: * Prior treatment with non-liposomal amphotericin B formulations (e.g., amphotericin B deoxycholate) for ≥4 days. * Documented hypersensitivity, severe immediate allergic reaction, or intolerance to liposomal amphotericin B. * History of a second malignancy (other than the index hematologic malignancy) treated within the past 3 years. * Active HIV infection, hepatitis B virus (HBV) infection (HBsAg-positive), hepatitis C virus (HCV) infection (RNA-positive), or syphilis. * Psychiatric disorders, cognitive impairment, or other conditions impairing compliance with study procedures or assessments. * Pregnant females, breastfeeding females, or individuals of reproductive potential unwilling to use effective contraception during treatment and for ≥3 months post-therapy. * Serum creatinine ≥2.0 × upper limit of normal (ULN). * Liver transaminases (ALT/AST) or alkaline phosphatase ≥5.0 × ULN. * Total bilirubin ≥3.0 × ULN (isolated bilirubin ≥3.0 × ULN is permitted if due to Gilbert's syndrome or hemolysis). * Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.